POA Pharma Scandinavia AB with offices in Gothenburg, Bergen, Hillerod and Helsinki primarily markets Pharmaceuticals and Medical Nutrition.
The company is young, but the employees' industry experience is considerable. More on http://www.poapharma.com.
– We are expanding strongly at the present. Over the next year we expect to sell in around 25 markets in the Americas, Europe and Asia.
Co-owner of US-distributor
Recently POA Pharma Scandinavia AB acquired a stake in Novam-Nutrition LLC, Oregon / USA and along with this also will also hold a directorship.
Novam-Nutrition's main focus is marketing of medical nutrition in Canada and the United States.
– Two of POA Pharma's product groups within Medical Nutrition are part of the cooperation:
□ Anti-secretory factor, AF, in the form of the products SPC-Flakes and Salovum for the treatment of inflammatory bowel diseases, Meniere’s disease, Mastitis and other disorders. AF is a Swedish research project based in Gothenburg and POA Pharma holds the global rights.
□ In-house developed and manufactured products within the area of PKU, an inherited metabolic disorder that requires daily and lifelong treatment.
Common to both product groups is that they are eligible for reimbursement in most countries, i.e. authorities pay for most of the treatment cost due to the vital importance of the treatment.
David Lindsley, RDN, LD, CD // President of NOVAM Nutrition makes the following statement:
”We have chosen to partner with the POA Group as we believe that the POA Group provides better quality, innovation and science to support the efficacy of all products in their portfolio. We are looking forward to contributing in the design, manufacture and distribution of future products.”
The availability of a total of 25 markets from 2015 will provide the POA Pharma significant growth opportunities in the coming years.
Questions will be answered by Tina Madsen Sandström at
Press contacts: Carl-Olof Börjeson
073-703 24 72Leave a reply →